Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetic macular edema with center involvement in at least one eye~* Type 1 or type 2 diabetes mellitus diagnosed 2 years prior to screening~* Laser photocoagulation in the study eye can be withheld for at least 3 months after randomization~Exclusion Criteria:~* Patients with uncontrolled systemic or ocular diseases~* Have any history of any intraocular surgery in the study eye within the past 6 months preceding screening~* Conditions that require chronic concomitant therapy with systemic or topical ocular corticosteroids~Other protocol-defined inclusion/exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab 0.3 mg (Type: EXPERIMENTAL): Participants received monthly intravitreal injections with 0.3 mg ranibizumab (6 mg/ml) for up to 12 months. At each monthly visit from month 1 and onwards, the evaluating physician decided whether an increase in the dose to 0.6 mg was needed according to set criteria. If the dose was increased, all subsequent administrations were of the higher dose unless treatment had been withheld for more than 45 days (for any reason), in which case injections restarted with the initial dose. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
- Ranibizumab 0.5 mg (Type: EXPERIMENTAL): Participants received monthly intravitreal injections with 0.5 mg ranibizumab (10 mg/ml) for up to 12 months. At each monthly visit from month 1 and onwards, the evaluating physician decided whether an increase in the dose to 1.0 mg was needed according to set criteria. If the dose was increased, all subsequent administrations were of the higher dose unless treatment had been withheld for more than 45 days (for any reason), in which case injections restarted with the initial dose. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
- Sham injection (Type: SHAM_COMPARATOR): Participants in the control group received 12 monthly sham intravitreal injections. The evaluation was performed using the same criteria for dose doubling as in active treatment groups. The injection was a mimicked by an empty syringe without a needle. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.

Based on this trial design, predict the completion outcome and termination type (if applicable).